82769-75-3Relevant articles and documents
Amino alcohols using the optically active amino alcohol derivative bi- Nord complex boron - -
-
Paragraph 0064; 0071-0076; 0274-0276; 0278-0280, (2021/04/16)
Disclosed are an amino alcohol-boron-binol complex as an intermediate, including Complex 3-1-1 shown below, and a method for preparing an optically active amino alcohol by using the same, wherein a racemic amino alcohol is resolved in an enationselective manner using a boron compound and a (R)- or (S)-binol, whereby an amino alcohol derivative with high optical purity can be prepared at high yield.
5-hydroxytryptamine re-absorption inhibitor crystal form and preparation method thereof
-
Paragraph 0045-0054, (2019/08/30)
The invention relates to a dapoxetine hydrochloride crystal form and a preparation method thereof, and belongs to the technical field of drug synthesis. The preparation method comprises: dissolving (S)-3-amino-3-phenylpropionic acid in an appropriate solvent, adding a reducing agent and a Lewis acid, and reducing to obtain (S)-3-amino-3-phenylpropanol; dissolving the (S)-3-amino-3-phenylpropanolin formic acid, and adding formaldehyde to produce (S)-3-dimethylamino-3-phenylpropanol; dissolving the (S)-3-dimethylamino-3-phenylpropanol in an organic solvent, adding an alkali and 1-fluoronaphthalene, carrying out heating stirring for 5-10 h, adding water and an organic solvent, extracting, carrying out spin drying on the organic phase, dissolving with a solvent, adding concentrated hydrochloric acid in a dropwise manner, and carrying out pressure reducing distillation to remove the solvent and the water; and re-crystallizing with a suitable solvent to obtain the dapoxetine hydrochloride.According to the present invention, the Cu-Ka radiation results of the obtained dapoxetine hydrochloride crystal form show that the characteristic peaks represented by 2[theta] angle are positioned at 6.24+/-0.2, 15.03+/-0.2, 18.87+/-0.2, 20.63+/-0.2 and 25.28+/-0.2 in the X-ray powder diffraction pattern.
Method for preparing dapoxetine hydrochloride
-
Paragraph 0048-0049; 0095; 0097, (2017/07/22)
The invention discloses a method for preparing dapoxetine hydrochloride. The method comprises the following steps: subjecting (s)-3-amino-3-phenylpropionic acid or an ester thereof to a reduction reaction in a reduction system prepared from a hydroborate and a boron trifluoride complex, so as to obtain an intermediate 1, i.e. (s)-3-amino-3-phenylpropanol; subjecting the (s) intermediate 1 to an Eschweiler-Clark reaction with formic acid and formaldehyde, so as to obtain an intermediate 2; subjecting the intermediate 2 to a Williamson ether forming reaction with 1-fluoronaphthalene, so as to obtain a free alkali, i.e. (s)-N,N-dimethyl-3-(1-naphthyloxy)phenyl propyl amine; subjecting the free alkali to a salt forming reaction with alcohol-acyl chloride or a chloride thereof, a hydrochloric acid organic solution or hydrochloric acid gas, thereby obtaining dapoxetine hydrochloride. According to the method, the synthesis route is low in production cost, the reaction conditions are mild, all the materials are readily available, the raw materials are low in toxicity, the reaction is simple in operation and high in safety, and the product is high in purity and yield and is environmentally friendly, so that the method is applicable to industrial large-scale production.
